Last reviewed · How we verify

NCT03710811

Observational Study of Drug Naive Diabetes Receiving Insulin Therapy

Status unknown Last updated 18 October 2018
What this trial tests

trial testing Insulin in Type 2 Diabetes in 150 participants. Status unknown.

Timeline
1 September 2017
Primary endpoint
30 August 2020
30 August 2021

Quick facts

Lead sponsorThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment150
Start date1 September 2017
Primary completion30 August 2020
Estimated completion30 August 2021
Sites2 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Who can join

Adults 20 to 70, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multi-centre, open-label trial to investigate the efficacy and possible mechanism of Continuous Subcutaneous Insulin Infusion treatment in patients with drug naive type 2 diabetes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effects of Early Intensive Insulin Therapy on Endothelial Progenitor Cells in Patients with Newly Diagnosed Type 2 Diabetes.
    Zhang W, Wang H, Liu F, Ye X, et al · · 2022 · cited 5× · PMID 34894328 · DOI 10.1007/s13300-021-01185-w

Verify or expand the search:

Other trials of Insulin

Trials testing the same drug.

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

Other The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03710811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing